Question 1

What is Soquelitinib?

Accepted Answer

Soquelitinib is a Other.

Question 2

How often does Soquelitinib appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 7 articles.

Question 3

When was Soquelitinib first tracked by Ergen?

Accepted Answer

First tracked on May 07, 2026.

Question 4

When was Soquelitinib last mentioned in news?

Accepted Answer

Last active on May 14, 2026.

Question 5

What is Soquelitinib's current news sentiment?

Accepted Answer

Aggregate sentiment score: 80 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Soquelitinib in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving Soquelitinib?

Accepted Answer

Corvus Soquelitinib Phase 1 Atopic Dermatitis Data (May 07, 2026, 7 articles).

Question 8

How did the "Corvus Soquelitinib Phase 1 Atopic Dermatitis Data" event impact Soquelitinib?

Accepted Answer

Soquelitinib, an investigational drug by Corvus Pharmaceuticals, showed positive safety and efficacy results in Phase 1 trials for atopic dermatitis, with potential for prolonged drug-free remissions. This strengthens its position as a promising treatment for autoimmune and inflammatory diseases.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.